Tiziana Life Sciences PLC Sponsored ADR Aktie News

BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation as a presenting company at BIO-Europe 2025.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Tuesday it has been invited to present at a major biotechnology conference in Riyadh, underscoring Saudi Arabia's push to position itself as a global hub for life sciences research and investment. The Nasdaq-listed biotech will attend the Life Science Innovation Forum, a two-day event hosted Oct. 1–2 at the King Saud bin Abdulaziz University for Heal...

BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares rose more than 10% in late morning trading on Thursday after the biotech company said it plans to advance development of TZLS-501, an antibody that blocks a key inflammatory pathway.  Tiziana noted that the therapy targets the interleukin-6 receptor, or IL-6R.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Thursday it plans to advance development of TZLS-501, an antibody that blocks a key inflammatory pathway, at a time when big drugmakers are paying closer attention to the area. The Boston-based biotech said the therap targets the interleukin-6 receptor, or IL-6R.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) is set to highlight the design of its mid-stage trial for an experimental multiple sclerosis treatment at a leading international neurology conference this week. The biotechnology company said it will present a poster at the 41st Congress of the European Committee for Treatment and Research of Multiple Sclerosis, or ECTRIMS, being held Sept.

BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has been awarded a US Department of Defense (DoD) research grant to advance its intranasal anti-CD3 therapy in traumatic spinal cord injury (SCI). The grant will support a three-year study examining the therapy in the acute phase of SCI, focusing on patients who present immediately following injury.